Enlaza Therapeutics
PrivateLast Round
Strategic
Sep 2, 2025
Total Funding Raised
$161M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Enlaza Therapeutics is a biotechnology company that develops covalent protein therapeutics using its proprietary War-Lock platform to create highly selective biologic drugs for cancer and other serious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enlaza Therapeutics Comparables
Compare Enlaza Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Matchpoint Therapeutics | 78% | |
| BridGene Biosciences | 74% | |
| Nexo Therapeutics | 73% |
Enlaza Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Sep 2, 2025 | ||||
| Series A | Apr 30, 2024 | ||||
| Seed | Dec 15, 2022 |
Enlaza Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A. M. Pappas & Associates | Series A |
| J.P. Morgan Private Capital | Series A |
| Frazier Life Sciences | Seed, Series A |
| Avalon Ventures | Series A, Seed |
| Amgen Ventures | Series A |
| Samantha | Series A |
| Alexandria Venture Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 100% MoM, reaching 1.9K.
- Sep 2, 2025
$15M raised in early funding.
Enlaza Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enlaza Therapeutics's valuation, stock price, and market status.
Is Enlaza a public or private company?
Enlaza is a private company.
What is the current stock price of Enlaza?
Enlaza is a private company with no public stock price. No recent secondary market data is available.
How much is Enlaza worth (valuation)?
Valuation information for Enlaza is not publicly available.
Can I buy Enlaza stock?
Enlaza shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Enlaza's last funding round?
Enlaza's most recent funding round was Early Funding on September 10, 2025.
Who are the main investors in Enlaza?
Key investors in Enlaza include J.P. Morgan Private Capital, Avalon Ventures, J.P. Morgan Asset Management.
Will Enlaza IPO soon?
No public IPO plans have been announced for Enlaza.
How can I track Enlaza secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Enlaza's secondary market activity and sign up for updates.